Myeloid Leukemia News and Research

RSS

Myeloid Leukemia is an aggressive (fast-growing) disease in which too many myeloblasts (immature white blood cells that are not lymphoblasts) are found in the bone marrow and blood. Also called acute myeloblastic leukemia, acute myelogenous leukemia, acute nonlymphocytic leukemia, AML, and ANLL.

Treg therapy ensures success of hematopoietic stem cell transplantation, without triggering GVHD

For blood cancer patients at high risk of relapse, hematopoietic stem cell transplantation (HSCT), the transplantation of blood-forming stem cells, is one of best options for treatment and a potential cure. Unfortunately, the most common complication of HSCT is graft-versus-host disease (GVHD), a serious and often deadly post-transplant complication that occurs when the newly transplanted donor cells recognize the recipient's own cells as foreign and react by attacking the cells in the patient's body.

4 Feb 2011

Inovio announces regulatory approval for Phase 2 trial to treat leukemia using new vaccine delivery device

Inovio Pharmaceuticals, a leader in the development of therapeutic and preventive vaccines against cancers and infectious diseases, announced today the regulatory approval of a Phase 2 clinical trial to treat leukemia utilizing Inovio's new ELGEN 1000 automated vaccine delivery device.

31 Jan 2011

FDA grants BioSante Orphan Drug designation for Melanoma Cancer Vaccine

BioSante Pharmaceuticals, Inc. today announced the receipt of Orphan Drug designation for its Melanoma Cancer Vaccine in the treatment of stage IIb to IV melanoma, from the FDA's Office of Orphan Products Development. Melanoma is the most deadly form of skin cancer.

25 Jan 2011

Researchers reveal how genetic mutation contributes to cancer development

Scientists around the world have been hot on the trail of a genetic mutation closely associated with some brain cancers and leukemia since the mutation's discovery in 2008. The hunt is now yielding fruit. In the Jan. 18, 2011 issue of Cancer Cell, researchers reveal how the mutation contributes to cancer development and suggest potential ways to counter its effects.

21 Jan 2011

Geron commences enrollment in imetelstat Phase 2 clinical trial in essential thrombocythemia

Geron Corporation today announced enrollment of the first patient in a Phase 2 clinical trial to evaluate the activity of the company's telomerase inhibitor drug, imetelstat (GRN163L), in patients with essential thrombocythemia (ET).

19 Jan 2011

Ridaforolimus achieves primary endpoint in Phase 3 trial for metastatic soft-tissue and bone sarcomas

ARIAD Pharmaceuticals, Inc., today announced top-line data showing that ridaforolimus, an investigational oral mTOR inhibitor, met the primary endpoint of improved progression-free survival (PFS) compared to placebo in the Phase 3 SUCCEED trial conducted in patients with metastatic soft-tissue or bone sarcomas who previously had a favorable response to chemotherapy.

19 Jan 2011

Quebec reimburses VIDAZA for treatment of blood cancer

Quebec patients with serious blood cancers (intermediate-2 and high-risk myelodysplastic syndrome and acute myeloid leukemia) now have publicly funded access to a new innovative therapy, VIDAZA® (azacitidine). Following a priority review and subsequent positive recommendation from the Conseil du medicament, patients now have the potential to significantly extend survival.

18 Jan 2011

MMRF, Synta collaborate for clinical development of ganetespib in multiple myeloma

The Multiple Myeloma Research Foundation (MMRF) today announced that it has entered into a joint collaboration with Synta Pharmaceuticals for the clinical development of ganetespib (formerly STA-9090) in patients with multiple myeloma.

13 Jan 2011

Pfizer initiates rolling submission of crizotinib NDA for ALK-positive advanced NSCLC

Pfizer Inc. announced today that it has initiated the rolling submission of a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for crizotinib (PF-02341066), an oral first-in-class anaplastic lymphoma kinase (ALK) inhibitor for the treatment of patients with advanced non-small cell lung cancer (NSCLC) whose tumors are ALK-positive. Pfizer expects to complete the submission in the first half of 2011.

13 Jan 2011

Cyclacel opens enrollment of sapacitabine Phase 3 trial for AML

Cyclacel Pharmaceuticals, Inc., today announced that it has opened enrollment of the SEAMLESS pivotal Phase 3 trial for the Company's sapacitabine oral capsules as a front-line treatment of elderly patients aged 70 years or older with newly diagnosed acute myeloid leukemia (AML) who are not candidates for intensive induction chemotherapy.

11 Jan 2011

Celator, Cephalon extend cancer research agreement

Celator Pharmaceuticals today announced that it has agreed with Cephalon, Inc. to extend an existing research agreement into the next phase of development. The research agreement provides for the utilization of Celator's proprietary technology in an ongoing drug development and life-cycle management program at Cephalon.

10 Jan 2011

New mechanisms of resistance to chemotherapy among leukemia patients

The interplay between a major tumor-suppressing gene, a truncated chromosome and two sets of microRNAs provides a molecular basis for explaining the less aggressive form of chronic lymphocytic leukemia, an international team of researchers reports today in the Jan. 4 edition of the Journal of the American Medical Association.

10 Jan 2011

Researchers demystify death of brain cells in Parkinson's patients

Just 5 percent of Parkinson's disease cases can be explained by genetic mutation, while the rest have no known cause. But a new discovery by researchers at The University of Texas Health Science Center San Antonio may begin to explain why the vast majority of Parkinson's patients develop the progressive neurodegenerative disease.

10 Jan 2011

SuperGen initiates enrollment in first human trial of SGI-110 in MDS and AML

SuperGen, Inc. today announced that it has enrolled the first patient in its first in human study of SGI-110, a second-generation hypomethylating agent, in patients with intermediate-2 or high-risk myelodysplastic syndromes (MDS) or acute myeloid leukemia (AML).

5 Jan 2011

EpiCept regains compliance with continued listing requirement of Nasdaq Capital Market

EpiCept Corporation today announced that it has received notification from the Nasdaq Listing Qualifications Department that it has regained compliance with the continued listing requirement of the Nasdaq Capital Market that it maintain a minimum market value of its listed securities of at least $35 million pursuant to Listing Rule 5550(b)(2).

3 Jan 2011

Myrexis initiates controlled two-arm Azixa Phase 2b clinical study in glioblastoma multiforme

EpiCept Corporation today reported that Myrexis, Inc. has initiated a controlled two-arm Phase 2b clinical study of Azixa™ as a front-line treatment for glioblastoma multiforme (GBM). Azixa™, a vascular disruption agent with potent anti-cancer activity, was discovered by EpiCept as part of its ASAP technology platform and licensed to Myrexis.

28 Dec 2010

Therapies to target self-renewing population of chemotherapy-resistant cells needed

Leukemia patients whose cancers express higher levels of genes associated with cancer stem cells have a significantly poorer prognosis than patients with lower levels of the genes, say researchers at the Stanford University School of Medicine. The finding is among the first to show that the cancer stem cell hypothesis - which posits that some cancers spring from and are replenished by a small, hardy population of self-renewing cells - can be used to predict outcomes in a large group of patients and one day to tailor treatments in the clinic.

22 Dec 2010

High LSC scores associated with adverse outcomes in AML patients

In an examination of leukemic stem cells (LSC), researchers have found that patients with acute myeloid leukemia who had higher activity of certain LSC genes had worse overall, event-free and relapse-free survival, according to a study in the December 22/29 issue of JAMA.

21 Dec 2010

EpiCept receives Israeli Ministry of Health approval for Ceplene

EpiCept Corporation today announced that the Israeli Ministry of Health has approved the marketing application for Ceplene®, indicated for remission maintenance and prevention of relapse in adult patients with Acute Myeloid Leukemia (AML) in first remission. Megapharm Ltd. is EpiCept's partner in Israel and upon Ministry of Health approval of labeling and other technical matters the company is expected to launch Ceplene® in the first quarter of 2011.

21 Dec 2010

Celator granted U.S. Patent covering CombiPlex technology platform

Celator Pharmaceuticals today announced the United States Patent and Trademark Office issued U.S Patent No. 7,850,990. This patent adds to the intellectual property surrounding Celator's innovative technology platforms and products.

17 Dec 2010

Myeloid Leukemia News and Research

Treg therapy ensures success of hematopoietic stem cell transplantation, without triggering GVHD

Inovio announces regulatory approval for Phase 2 trial to treat leukemia using new vaccine delivery device

FDA grants BioSante Orphan Drug designation for Melanoma Cancer Vaccine

Researchers reveal how genetic mutation contributes to cancer development

Geron commences enrollment in imetelstat Phase 2 clinical trial in essential thrombocythemia

Ridaforolimus achieves primary endpoint in Phase 3 trial for metastatic soft-tissue and bone sarcomas

Quebec reimburses VIDAZA for treatment of blood cancer

MMRF, Synta collaborate for clinical development of ganetespib in multiple myeloma

Pfizer initiates rolling submission of crizotinib NDA for ALK-positive advanced NSCLC

Cyclacel opens enrollment of sapacitabine Phase 3 trial for AML

Celator, Cephalon extend cancer research agreement

New mechanisms of resistance to chemotherapy among leukemia patients

Researchers demystify death of brain cells in Parkinson's patients

SuperGen initiates enrollment in first human trial of SGI-110 in MDS and AML

EpiCept regains compliance with continued listing requirement of Nasdaq Capital Market

Myrexis initiates controlled two-arm Azixa Phase 2b clinical study in glioblastoma multiforme

Therapies to target self-renewing population of chemotherapy-resistant cells needed

High LSC scores associated with adverse outcomes in AML patients

EpiCept receives Israeli Ministry of Health approval for Ceplene

Celator granted U.S. Patent covering CombiPlex technology platform

Industry Focus eBook - Cell & Gene Therapy (1st Edition) eBook

Advancing Neuroscience Research Through Collaboration and Patient-Centered Innovation

The impact of vibration on microscopy

How Omics Technologies Are Transforming Biological Research and Drug Discovery

Latest News